TABLE 6

Univariate and Multivariate Analyses of Potential Factors Contributing to PFS, Part 2

	PFS (mo)			Multivariate analysis
Factors	Median	95% CI	Univariate analysis (P)	HR and 95% CI	P
Liver tumor burden on ¹⁸F-FDG PET
0 lesions	20.8	17.4–24.1	0.034
1 lesion	27.8	20.9–34.7
2 to ≤5 lesions	16.2	11.5–20.9
>5 lesions	17.9	14.1–21.7
Not assessed	28.2	0.0–58.7
Bone tumor burden on ¹⁸F-FDG PET
0 lesions	22.4	19.3–25.5	<0.001		0.001
1 lesion	13.3	1.4–25.1		1.0 (0.2–4.1)	0.982
2 to ≤5 lesions	10.5	8.4–12.5		1.7 (0.4–7.4)	0.479
>5 lesions	11.5	0.0–24.9		2.2 (0.5–9.4)	0.304
Not assessed	12.0	—		1.2 (0.3–5.2)	0.848
Lymph node tumor burden on ¹⁸F-FDG PET
0 lesions	21.6	18.6–24.7	<0.001		0.050
1 lesion	17.9	10.9–25.0		1.2 (0.5–3.1)	0.587
2 to ≤5 lesions	15.4	12.3–18.6		1.3 (0.5–3.4)	0.552
>5 lesions	6.5	4.5–8.5		1.3 (0.5–3.3)	0.563
Not assessed	37.2	7.1–67.3		3.5 (1.2–10.1)	0.019
Lung tumor burden on ¹⁸F-FDG PET
0 lesions	19.9	17.5–22.3	<0.001
1 lesion	18.4	16.5–20.3
2 to ≤5 lesions	3.7	0.0–21.3
>5 lesions	5.3	1.5–9.2
Grading of PRRT
2 to ≤3 cycles	13.6	8.6–18.5	0.907
4 to ≤5 cycles	18.0	15.2–20.8
6 to ≤7 cycles	25.0	20.9–29.2
8 to ≤10 cycles	26.8	16.7–36.8